Jasco Pharmaceuticals, LLC to Present its Preclinical PIM Inhibitor Program at the American Association for Cancer Research Annual Meeting
Published: Apr 02, 2013
WOBURN, Mass.--(BUSINESS WIRE)--Jasco Pharmaceuticals, LLC announced that preclinical data on its PIM inhibitor program would be presented at the American Association for Cancer Research (AACR) Annual Meeting 2013 to be held on April 6-10 in Washington, DC. The poster entitled “PIM2 Inhibitor as a Targeted Therapy for the Treatment of Multiple Myeloma Patients with Specific Genetic Signatures” will be presented on Sunday, April 7, 2013 from 1:00 PM - 5:00 PM. The poster session is titled, “Experimental and Molecular Therapeutics 8” in Exhibit Hall A-C, Poster Section 43, and Abstract Number: 1049. The results will include data generated in collaboration with the Roswell Park Cancer Institute in Buffalo, NY.